Comments from Dr. Michael Cooney:
One of the decisive factors in our practice choosing to introduce Calmare Therapy was an independent scientific report published by Thomas J. Smith, MD, Endowed Chair of Palliative Care Research and Medical Director, at Virginia Commonwealth University’s Massey Cancer Center. The 2011 study, one of the first detailed studies conducted in the U. S. since Calmare received FDA clearance, concluded, “Patient-specific cutaneous electrostimulation (the Calmare therapeutic process) with the MC5-A Calmare device appears to dramatically reduce pain in refractory CIPN patients with no toxicity.”
- Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer
NCT ID: NCT01196442
Sponsor: Virginia Commonwealth University, Massey Cancer Center
Principal Investigator: Thomas J. Smith
Protocol IDs: MCC-13098, NCI-2010-01945
- Electrical Stimulation Therapy Using the MC5-A Scrambler in Reducing Peripheral Neuropathy Caused by Chemotherapy
Virginia Commonwealth University, Massey Cancer Center
Thomas J. Smith
CDR0000644516, MCV-MCC-12110, MCC-12110
RATIONALE: Electronic stimulation using a MC5-A Scrambler may help relieve pain in patients who develop peripheral neuropathy while undergoing chemotherapy treatments for cancer.
PURPOSE: This phase II trial is studying how well MC5-A Scrambler therapy works in reducing peripheral neuropathy caused by chemotherapy.